This is a non-interventional, study to assess demographic characteristics and patient reported outcomes in China patients with SEA treated with benralizumab

Trial Identifier: D3250R00131
Sponsor: AstraZeneca
Start Date: July 2025
Primary Completion Date: January 2026
Study Completion Date: January 2026
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Beijing, China
China Binzhou, China
China Huzhou, China
China Jinan, China
China Jinhua, China
China Jining, China
China Linyi, China
China Nanchang, China
China Nanjing, China
China Shanghai, China
China Zhengzhou, China